News & Events
September 6, 2018
Doris Duke Charitable Foundation Awards Grant to Critical Path Institute to Advance Therapies for Sickle Cell DiseaseContacts: Kissy Black, Critical Path Institute [email protected], 615.298.1144 Kristin Roth-Schrefer, Communications Director [email protected], 212.974.7003 Nina Chung, Communications Associate [email protected], 212.974.7006 Critical Path Institute (C-Path) Will Plan a Consortium of Stakeholders Focused on Developing Therapies for Sickle Cell Disease NEW YORK, September 6, 2018 — In a continuing effort to spur advancements in treating...
August 10, 2018
CPAD’s Has Two Posters Accepted to Alzheimer’s Association International ConferenceThe Alzheimer’s Association International Conference (AAIC) is the largest annual scientific meeting with focus on Alzheimer disease (AD). More than 6,500 researchers and participants from pharma, academia, patent-advocacy organizations and other groups came together in Chicago between July 22nd and 26th to exchange the latest developments and research results. Each year, on behalf of our...
August 10, 2018
Evidence-Based Treatment Decisions In Transplantation: The Right Dose & Regimen for the Right Patient/Individualized TreatmentThe following originally appeared on fda.gov: Summary: The Food and Drug Administration is announcing the following public workshop titled “Evidence-Based Treatment Decisions In Transplantation: The Right Dose & Regimen for the Right Patient/Individualized Treatment. This public workshop is planned and presented in collaboration with the Transplant Therapeutics Consortium (TTC), a public-private partnership between the FDA, transplantation...
August 2, 2018
International Neonatal Consortium Multi-stakeholder Survey
You are invited to participate in a study commissioned by the International Neonatal Consortium (INC) because we believe your experiences can assist us in assessing communication practices in neonatal intensive care units (NICUs) regarding research or research practice.
July 26, 2018
First-ever biomarker qualified for Parkinson’s is a vital step toward improved clinical trialsFOR IMMEDIATE RELEASE Contact: Kissy Black 615.298.1144 [email protected] Tucson, AZ — July 26, 2018 – The Critical Path Institute’s (C-Path) Critical Path for Parkinson’s Consortium (CPP), in partnership with Parkinson’s UK, announces that the European Medicines Agency (EMA) has issued a positive qualification opinion on an imaging test (biomarker) as a tool to enrich...